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Abstract 
Primary cutaneous marginal zone lymphoma (PCMZL) is a B cell lymphoma with a very 
low metastatic rate. Radiographic monitoring for internal involvement may be indicated 
initially. Favored treatments include radiation and excision. Radiation has high risk of 
local recurrence. Excision carries risk of infection and scarring. We report successful 
long-term treatment of recurrent PCMZL via intralesional steroid injections into new 
lesions as they arose. This was preferred by the patient over her prior radiation and 
surgical treatments. Intralesional steroids have the advantages of being simple and well 
tolerated, without exposure to ionizing radiation or to the infection and scarring 
associated with surgery. 
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Introduction 
The incidence of primary cutaneous lymphomas is approximately 10 cases per million 
inhabitants per year, and they are the most frequent extra-nodal lymphomas.1 Cutaneous 
B cell lymphoma (CBC L) comprises 25 to 30% of primary cutaneous lymphoma, and 
data and guidelines on management are lacking.2,3 CBC L prognosis differs greatly by 
subtype. Indolent CBC L includes primary cutaneous follicle centers lymphoma and 
primary cutaneous marginal zone lymphoma (PCMZL).  PCMZL does not generally 
reduce lifespan.4 
 
Case report 
 
In 2008 a 53-year-old Caucasian woman presented with a pink nodule on her right 
eyebrow. It was initially shaved off, but recurred in 2009, at which time punch biopsy 
revealed PCMZL. PET Scan, done as per the current management guidelines by the 
European Organization for Research and Treatment of Cancer and International Society 
for Cutaneous Lymphoma, did not reveal systemic involvement.5 The eyebrow was 
treated with radiation therapy with resolution. In 2011 the lesion recurred, was re-
biopsied, showing recurrent PCMZL. It was again treated with radiation. In 2013 she 
developed three new similar lesions, one on the right shoulder and one on each arm. All 
three were surgically excised and biopsy again revealed PCMZL. Although she denied 
fever, chills, sweats or weight loss, she was referred to oncology for restaging. Bone 
marrow biopsy and a second PET scan revealed no concerning findings. Oncology 
deemed her to be without systemic involvement. One month after her oncology work up, 
she presented with three new plaques, one on the right forearm and two on the left 
shoulder. This time, after being presented with the option of radiation or surgery, she 
chose instead to receive intralesional triamcinolone injections. The lesions received a 
total of 0.85 mL of 5 mg / cc triamcinolone. The procedure was well tolerated. Lesions 
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improved dramatically. Six weeks later she was again injected, this time 0.2 mL total. 
Lesions fully resolved.  Over the next three and a half years she was seen at four to eight 
week intervals and any new lesions were injected as above.  During the next two years, 
the visits were gradually decreased to six-month intervals. All injections were well 
tolerated. The only adverse effects were indentations at some of the injection sites; the 
patient was not bothered by this. 
 
 
Fig A: Elevated pink nodule on eyebrow with slight central scale.  Eyebrow is preserved 
but on palpation there is the feeling of depth.  This is after failure of radiation two times 
and excision.  
 
 
 
 
Fig B: Intralesional steroids caused rapid resolution without scar and without recurrence 
for 2 years. 
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Discussion 
 
Because systemic involvement is seldom seen, PCMZL is typically treated with radiation, 
excision, and/or rituximab (anti-CD20 monoclonal antibody).6 Rituximab carries risk of 
serious side effects.7 Surgery carries risk of infection as well as scar, and data on margins 
and recurrence is lacking.4 Radiation therefore has been a mainstay of PCMZL therapy.  
Unfortunately, radiation carries reported recurrence risks ranging from 25 to 63%.1,8 
Topical steroids can be tried as well but show limited efficacy. 
 
Intralesional steroids therefore present a reasonable treatment. They are more cost 
effective and easier to administer than the other therapies currently used for the treatment 
of PCMZL.9 Reported risks include recurrence, atrophy, and temporary erythema.10 The 
patient in this report experienced limited local atrophy. She preferred this to the scars left 
by plastic surgery excision.  Unlike her experience with radiation, none of the lesions 
treated with intralesional steroids recurred.  
 
Current management guidelines by the European Organization for Research and 
Treatment of Cancer and International Society for Cutaneous Lymphoma do not mention 
intralesional corticosteroids in the treatment of PCMZL, even though there have been a 
few reports, including ours, of successful treatment with intralesional steroids.5,9,10,11 We 
propose that close monitoring with intralesional steroid injection of new lesions may be 
an effective and well-tolerated way to treat chronic PCMZL, and that larger controlled 
trials of this therapy should be encouraged. 
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